Wyeth Pharmaceuticals
This article was originally published in The Gray Sheet
Executive Summary
ReFacto R2 kit for recombinant antihemophilic factor VIII delivery, cleared via biologics license application supplement Sept. 10, provides the first available needleless reconstitution process for powdered factor VIII and a pre-filled diluent component for hemophilia treatment, the firm says. Eliminating two of the three needles used in Wyeth's previous ReFacto delivery kit, which was not pre-filled, the revised version incorporates a syringe made by Vetter, a vial adapter manufactured by Medimop and Braun infusion components. Priced the same as the earlier version, the next generation kit adds convenience, takes less time to use and will facilitate competition with factor VIII firm Baxter, Wyeth notes. A fourth quarter launch is anticipated...
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.